Yuhui Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuhui Sun has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Tao Song
Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, China
5 shared publications - Chunquan Sun
Tsinghua University Yuquan Hospital (Tsinghua University Hospital of Integrative Traditional Chinese and Western Medicine), Beijing, China
4 shared publications - Hongyan Zhang
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
4 shared publications - Lan Cheng
Beijing Puren Hospital, Beijing, China
4 shared publications - Lianxin Wang
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
4 shared publications - Liran Ma
Beijing GULOU Hospital of Traditional Chinese Medicine, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Heat stress and air pollution in female reproductive health: from pathological alterations to molecular mechanisms
1. Globally, women’s reproductive health is confronting increasingly severe challenges. According to data from multiple countries worldwide, infertility affects millions of couples, while the incid...
- 5 November 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Open AccessHeat stress and air pollution in female reproductive health: from pathological alterations to molecular mechanisms
1. Globally, women’s reproductive health is confronting increasingly severe challenges. According to data from multiple countries worldwide, infertility affects millions of couples, while the incid...
- Open Access
- 21 April 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e84867
Correction: Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study
[This corrects the article DOI: 10.2196/84803.].
- 21 April 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e84867
Open AccessCorrection: Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study
[This corrects the article DOI: 10.2196/84803.].
- Open Access
- 25 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e84803
Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study
Background: Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient. Objective: This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS. Methods: This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses. Results: Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027. Conclusions: This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. Trial Registration: ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 International Registered Report Identifier (IRRID): DERR1-10.2196/84803
- 25 March 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e84803
Open AccessReal-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study
Background: Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient. Objective: This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS. Methods: This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses. Results: Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027. Conclusions: This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. Trial Registration: ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 International Registered Report Identifier (IRRID): DERR1-10.2196/84803
- Open Access
- 26 December 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Cold climate dual threats: lagged and nonlinear effects of air pollution and meteorological extremes on acute myocardial infarction risk
Acute myocardial infarction (AMI) remains a major health concern in cold regions, where extreme meteorological conditions and air pollution can jointly ele
- 26 December 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessCold climate dual threats: lagged and nonlinear effects of air pollution and meteorological extremes on acute myocardial infarction risk
Acute myocardial infarction (AMI) remains a major health concern in cold regions, where extreme meteorological conditions and air pollution can jointly ele
- Open Access
- 25 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Real-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study (Preprint)
BACKGROUND Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient. OBJECTIVE This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS. METHODS This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses. RESULTS Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027. CONCLUSIONS This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. CLINICALTRIAL ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/84803
- 25 September 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessReal-World Effectiveness and Safety of Liuwei Dihuang Pill for Menopausal Syndrome: Protocol for a Prospective, Observational, Multicenter Cohort Study (Preprint)
BACKGROUND Menopausal syndrome (MPS) results from declining ovarian function and estrogen fluctuations during the menopausal transition, typically presenting with vasomotor, psychological, and metabolic symptoms that impair quality of life. Current treatments, including hormone replacement therapy and nonhormonal medications, are limited by safety concerns and adverse effects. The Liuwei Dihuang (LWDH) pill, a classical traditional Chinese medicine formula, is widely used for kidney-yin deficiency and menopausal symptoms such as hot flashes, insomnia, depression, and anxiety. Preliminary studies suggest favorable efficacy and safety; however, robust real-world evidence, particularly in combination with conventional Western therapy, remains insufficient. OBJECTIVE This study aims to evaluate the real-world effectiveness and safety of LWDH in combination with conventional Western therapy for MPS. METHODS This prospective, multicenter, real-world, observational cohort study will be conducted at 8 centers in China from March 9, 2025, to December 2026. A total of 1000 patients with MPS in a real-time clinical setting will be allocated to either the exposure group (conventional therapy plus LWDH) or the nonexposure group (conventional therapy alone). The primary outcome is the change in the modified Kupperman Index. The secondary outcomes encompass changes in the Menopausal Quality of Life Scale, serum sex hormone levels, traditional Chinese medicine syndrome scores, and metabolic parameters. Metabolomics analyses will be conducted to explore potential mechanisms. Safety will be assessed by monitoring adverse events and clinically significant abnormalities in vital signs or laboratory parameters. Assessments will be conducted at baseline and at 2 and 4 weeks, with a subsequent 2-week follow-up. Propensity score–based inverse probability of treatment weighting will be applied to balance baseline covariates, and weighted regression models will be used for comparative analyses. RESULTS Participant recruitment and enrollment began in March 2025. It is expected that by December 2026, a total of 1000 participants will be recruited. At present, patient recruitment is ongoing, and preliminary organization and analysis of medical record data are underway. Blood sample collection for metabolomics analysis is also in progress. Final data collection is expected to be completed in March 2027. We expect to generate evidence to support clinical decision-making, with results anticipated to be published in esteemed, peer-reviewed health research journals by December 2027. CONCLUSIONS This study will assess the clinical effectiveness, safety, and potential mechanisms of LWDH in the treatment of MPS in real-world settings, providing a scientific basis for its use in clinical practice. CLINICALTRIAL ClinicalTrials.gov NCT06874738; https://clinicaltrials.gov/study/NCT06874738 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/84803
- Open Access
- 12 March 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (5) , e70755
The Impact of High lncRNA Expression on Clinicopathological Characteristics and Prognosis of Endometrial Cancer Patients: A Meta‐Analysis
Backgrounds: A growing number of systematic bioinformatics analyses were conducted to investigate the mechanism of interaction between long non‐coding RNA (lncRNA) and endometrial carcinoma (EC) to predict the prognosis. However, there is no evidence‐based evidence that abnormal lncRNA expression is strongly associated with the pathological characteristics and prognosis of EC patients. In this meta‐analysis, we systematically evaluated the relationship between upregulated lncRNA expression levels and clinicopathological features, five‐year survival rate, and progression‐free survival (PFS).Methods: A systematic search was performed across seven reputable databases, namely the China National Knowledge Infrastructure, Wanfang, Wipu, PubMed, Web of Science, Cochrane Library, and Embase, encompassing the period from the inception of each database until November 27, 2022. Heterogeneity among the studies was assessed through the application of Cochran's Q and I2 statistics. All statistical analyses were conducted using Stata 14.0 software.Results: This study encompassed 30 clinical studies, involving a total of 2469 EC patients, and examined the expression of 24 lncRNAs, which were upregulated in EC samples. EC patients with higher expression of lncRNAs showed a later FIGO stage (OR = 1.94, 95% CI: 1.29 ~ 2.91), a poorer histological grade (OR = 3.40, 95% CI: 2.51 ~ 4.60), earlier deep myometrial invasion (OR = 2.57, 95% CI: 1.94 ~ 3.41), a higher likelihood of lymphatic vascular space infiltration (OR = 2.86, 95% CI: 1.15 ~ 7.14), an increased propensity for lymph node metastasis (OR = 2.89, 95% CI: 1.82 ~ 4.60), and a greater likelihood of distant metastasis (OR = 2.39, 95% CI: 1.33 ~ 4.30). All of these were statistically significant (p < 0.05). Furthermore, EC patients with a higher expression level of lncRNAs were significantly associated with five‐year survival (p < 0.05) and PFS (p < 0.05).Conclusions: High expression levels of upregulated lncRNAs in EC patients are associated with unfavorable clinicopathological features, a poor five‐year survival rate, and PFS. It serves as a detrimental prognostic factor and might be a biomarker and therapeutic target for EC.
- 12 March 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (5) , e70755
Open AccessThe Impact of High lncRNA Expression on Clinicopathological Characteristics and Prognosis of Endometrial Cancer Patients: A Meta‐Analysis
Backgrounds: A growing number of systematic bioinformatics analyses were conducted to investigate the mechanism of interaction between long non‐coding RNA (lncRNA) and endometrial carcinoma (EC) to predict the prognosis. However, there is no evidence‐based evidence that abnormal lncRNA expression is strongly associated with the pathological characteristics and prognosis of EC patients. In this meta‐analysis, we systematically evaluated the relationship between upregulated lncRNA expression levels and clinicopathological features, five‐year survival rate, and progression‐free survival (PFS).Methods: A systematic search was performed across seven reputable databases, namely the China National Knowledge Infrastructure, Wanfang, Wipu, PubMed, Web of Science, Cochrane Library, and Embase, encompassing the period from the inception of each database until November 27, 2022. Heterogeneity among the studies was assessed through the application of Cochran's Q and I2 statistics. All statistical analyses were conducted using Stata 14.0 software.Results: This study encompassed 30 clinical studies, involving a total of 2469 EC patients, and examined the expression of 24 lncRNAs, which were upregulated in EC samples. EC patients with higher expression of lncRNAs showed a later FIGO stage (OR = 1.94, 95% CI: 1.29 ~ 2.91), a poorer histological grade (OR = 3.40, 95% CI: 2.51 ~ 4.60), earlier deep myometrial invasion (OR = 2.57, 95% CI: 1.94 ~ 3.41), a higher likelihood of lymphatic vascular space infiltration (OR = 2.86, 95% CI: 1.15 ~ 7.14), an increased propensity for lymph node metastasis (OR = 2.89, 95% CI: 1.82 ~ 4.60), and a greater likelihood of distant metastasis (OR = 2.39, 95% CI: 1.33 ~ 4.30). All of these were statistically significant (p < 0.05). Furthermore, EC patients with a higher expression level of lncRNAs were significantly associated with five‐year survival (p < 0.05) and PFS (p < 0.05).Conclusions: High expression levels of upregulated lncRNAs in EC patients are associated with unfavorable clinicopathological features, a poor five‐year survival rate, and PFS. It serves as a detrimental prognostic factor and might be a biomarker and therapeutic target for EC.
- Open Access
- 15 January 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2451766
Gut microbiota and endometrial cancer: research progress on the pathogenesis and application
As one of the three major malignant tumors in women, the morbidity of endometrial cancer is second only to that of cervical cancer and is increasing yearly. Its etiological mechanism is not clear, and the risk factors are numerous and common and are closely related to obesity, hypertension, diabetes, etc. The gut microbiota has many strains, which play a considerable part in normal digestion and absorption in the human body and the regulation of the immune response. In the last few years, research on the gut microbiota has been unprecedentedly popular, and it has been confirmed that the gut microbiota closely correlates with the occurrence and development of all kinds of benign and malignant diseases. In this article, the effects of the gut microbiota and its metabolites on the occurrence and development of endometrial cancer is reviewed, and its application in the prevention, diagnosis and treatment of endometrial cancer is explored.
- 15 January 2025
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2451766
Open AccessGut microbiota and endometrial cancer: research progress on the pathogenesis and application
As one of the three major malignant tumors in women, the morbidity of endometrial cancer is second only to that of cervical cancer and is increasing yearly. Its etiological mechanism is not clear, and the risk factors are numerous and common and are closely related to obesity, hypertension, diabetes, etc. The gut microbiota has many strains, which play a considerable part in normal digestion and absorption in the human body and the regulation of the immune response. In the last few years, research on the gut microbiota has been unprecedentedly popular, and it has been confirmed that the gut microbiota closely correlates with the occurrence and development of all kinds of benign and malignant diseases. In this article, the effects of the gut microbiota and its metabolites on the occurrence and development of endometrial cancer is reviewed, and its application in the prevention, diagnosis and treatment of endometrial cancer is explored.
- Open Access
- 1 April 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (4) , 1980-1996
Microbiome in gynecologic malignancies: a bibliometric analysis from 2012 to 2022
Microbiome and microbial dysbiosis have been proven to be involved in the carcinogenesis and treatment of gynecologic malignancies. However, there is a noticeable gap in the literature, as no comprehensive papers have covered general information, research status, and research frontiers in this field. This study addressed this gap by exploring the relationship between the gut and female reproductive tract (FRT) microbiome and gynecological cancers from a bibliometric perspective. Using VOSviewer 1.6.18, CiteSpace 6.1.R6, and HistCite Pro 2.1 software, we analyzed data retrieved from the Web of Science (WOS) Core Collection (WoSCC) database. Our dataset, consisting of 204 articles published from 2012 to 2022, revealed a consistent and upward publication trend. The United States and the United Kingdom were the primary driving forces, attributed to their prolificacy, high-quality output, and extensive cooperation. The University of Arizona Cancer Center, which is affiliated with the United States, ranked first among the top ten most prolific institutions. Frontiers in Cellular and Infection Microbiology emerged as the leading publisher. Herbst-Kralovetz MM led as the most productive author. Mitra A was the most influential author. Cervical cancer is notably associated with the microbiome, while endometrial and ovarian cancers are receiving increased attention in the last year. Intersections between the gut microbiome and estrogen are of growing importance. Current research focuses on identifying specific microbial species for etiological diagnosis, while frontiers mainly focus on the anticancer potential of microorganisms, such as regulating the effects of immune checkpoint inhibitors. In conclusion, this study sheds light on a novel and burgeoning direction of research, providing a one-stop overview of the microbiome in gynecologic malignancies. Its findings aim to help young researchers to identify research directions and future trends for ongoing investigations.
- 1 April 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (4) , 1980-1996
Open AccessMicrobiome in gynecologic malignancies: a bibliometric analysis from 2012 to 2022
Microbiome and microbial dysbiosis have been proven to be involved in the carcinogenesis and treatment of gynecologic malignancies. However, there is a noticeable gap in the literature, as no comprehensive papers have covered general information, research status, and research frontiers in this field. This study addressed this gap by exploring the relationship between the gut and female reproductive tract (FRT) microbiome and gynecological cancers from a bibliometric perspective. Using VOSviewer 1.6.18, CiteSpace 6.1.R6, and HistCite Pro 2.1 software, we analyzed data retrieved from the Web of Science (WOS) Core Collection (WoSCC) database. Our dataset, consisting of 204 articles published from 2012 to 2022, revealed a consistent and upward publication trend. The United States and the United Kingdom were the primary driving forces, attributed to their prolificacy, high-quality output, and extensive cooperation. The University of Arizona Cancer Center, which is affiliated with the United States, ranked first among the top ten most prolific institutions. Frontiers in Cellular and Infection Microbiology emerged as the leading publisher. Herbst-Kralovetz MM led as the most productive author. Mitra A was the most influential author. Cervical cancer is notably associated with the microbiome, while endometrial and ovarian cancers are receiving increased attention in the last year. Intersections between the gut microbiome and estrogen are of growing importance. Current research focuses on identifying specific microbial species for etiological diagnosis, while frontiers mainly focus on the anticancer potential of microorganisms, such as regulating the effects of immune checkpoint inhibitors. In conclusion, this study sheds light on a novel and burgeoning direction of research, providing a one-stop overview of the microbiome in gynecologic malignancies. Its findings aim to help young researchers to identify research directions and future trends for ongoing investigations.
- Open Access
- 2 August 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11, 1172532
Short-term effects of air pollution and weather changes on the occurrence of acute aortic dissection in a cold region
Background: Air pollution and severe weather conditions can adversely affect cardiovascular disease emergencies. Nevertheless, it remains unclear whether air pollutants and low ambient temperature can trigger the occurrence of acute aortic dissection (AAD) in cold regions.Methods: We applied a retrospective analysis to assess the short-term effects of air pollution and ambient temperature on the occurrence of AAD in Harbin, China. A total of 564 AAD patients were enrolled from a major hospital in Harbin between January 1, 2017, and February 5, 2021. Weather condition data and air pollutant concentrations, including fine particulate matter smaller than 10 μm (PM10) and 2.5 μm in diameter (PM2.5), nitrogen dioxide (NO2), sulfur dioxide (SO2), carbon monoxide (CO), and ozone (O3), were collected every day. Conditional logistic regressions and correlation analysis were applied to analyze the relationship of environmental and atmospheric parameters with AAD occurrence at lags of 0 to 7 days. Specifically, we appraised the air quality index, CO, NO2, SO2, O3, PM10, PM2.5, temperature, dew point temperature, atmospheric pressure, and cloud amount.Results: A total of 1,496 days at risk were assessed, of which 564 patients developed AAD. Specifically, AAD did not occur on 1,043 (69.72%) days, while 1 or more cases occurred on 453 (30.28%) days. Several pollution and weather predictors for AAD were confirmed by multilevel modeling. The air quality index (p = 0.0012), cloud amount (p = 0.0001), and concentrations of PM2.5 (p = 0.0004), PM10 (p = 0.0013), NO2 (p = 0.0007) and O3 (p = 0.0001) predicted AAD as early as 7 days before the incident (lag of 7 days) in the study period. However, only concentrations of the air pollutants NO2 (p = 0.0468) and O3 (p = 0.011) predicted the occurrence of AAD after the COVID-19 outbreak. Similar predictive effects were observed for temperature, dew point temperature, and atmospheric pressure (all p < 0.05) on all days.Conclusion: The risk of AAD is closely related to air pollution and weather characteristics in Harbin. While causation was not determined, the impact of air pollutants on the risk of AAD was reduced after the COVID-19 outbreak.
- 2 August 2023
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 11, 1172532
Open AccessShort-term effects of air pollution and weather changes on the occurrence of acute aortic dissection in a cold region
Background: Air pollution and severe weather conditions can adversely affect cardiovascular disease emergencies. Nevertheless, it remains unclear whether air pollutants and low ambient temperature can trigger the occurrence of acute aortic dissection (AAD) in cold regions.Methods: We applied a retrospective analysis to assess the short-term effects of air pollution and ambient temperature on the occurrence of AAD in Harbin, China. A total of 564 AAD patients were enrolled from a major hospital in Harbin between January 1, 2017, and February 5, 2021. Weather condition data and air pollutant concentrations, including fine particulate matter smaller than 10 μm (PM10) and 2.5 μm in diameter (PM2.5), nitrogen dioxide (NO2), sulfur dioxide (SO2), carbon monoxide (CO), and ozone (O3), were collected every day. Conditional logistic regressions and correlation analysis were applied to analyze the relationship of environmental and atmospheric parameters with AAD occurrence at lags of 0 to 7 days. Specifically, we appraised the air quality index, CO, NO2, SO2, O3, PM10, PM2.5, temperature, dew point temperature, atmospheric pressure, and cloud amount.Results: A total of 1,496 days at risk were assessed, of which 564 patients developed AAD. Specifically, AAD did not occur on 1,043 (69.72%) days, while 1 or more cases occurred on 453 (30.28%) days. Several pollution and weather predictors for AAD were confirmed by multilevel modeling. The air quality index (p = 0.0012), cloud amount (p = 0.0001), and concentrations of PM2.5 (p = 0.0004), PM10 (p = 0.0013), NO2 (p = 0.0007) and O3 (p = 0.0001) predicted AAD as early as 7 days before the incident (lag of 7 days) in the study period. However, only concentrations of the air pollutants NO2 (p = 0.0468) and O3 (p = 0.011) predicted the occurrence of AAD after the COVID-19 outbreak. Similar predictive effects were observed for temperature, dew point temperature, and atmospheric pressure (all p < 0.05) on all days.Conclusion: The risk of AAD is closely related to air pollution and weather characteristics in Harbin. While causation was not determined, the impact of air pollutants on the risk of AAD was reduced after the COVID-19 outbreak.